Source comparison
CJC-1295 No DAC & Ipamorelin vs Other Fat Loss Peptides: Full Comparison
The peptide research landscape includes multiple compounds marketed for fat loss. Here's how CJC-1295 no DAC & Ipamorelin compare to the primary alternatives in mechanism, selectivity, and practical application. CJC-1295 no DAC + Ipamorelin GHRH analogue + sel
This comparison does not assign a generated winner or score.
- The peptide research landscape includes multiple compounds marketed for fat loss. Here's how CJC-1295 no DAC & Ipamorelin compare to the primary alternatives in mechanism, selectivity, and practical application.
- CJC-1295 no DAC + Ipamorelin
- GHRH analogue + selective ghrelin agonist; pulsatile GH secretion
- ~30 min (both)
- HSL activation via GH peaks; suppresses LPL; improves insulin sensitivity
- Highly selective. No cortisol or prolactin elevation; minimal appetite increase
- Best for lean individuals targeting 6–9% body fat reduction with lean mass preservation; requires fasted dosing and caloric deficit
- AOD-9604
- Modified C-terminal fragment of GH (hGH 176-191); stimulates lipolysis without GH receptor binding
- ~2 hours
- Direct HSL activation in adipocytes; no IGF-1 elevation
- No impact on blood glucose or insulin; no anabolic effects on lean mass
- Best for pure fat oxidation without muscle preservation; useful when GH receptor activation is contraindicated; less effective than full GH secretagogues
- Tesamorelin
- GHRH analogue; stimulates endogenous GH secretion
- ~26 min
- HSL activation; reduces visceral adipose tissue (VAT) specifically
- FDA-approved for HIV-associated lipodystrophy; very clean side effect profile; no ghrelin pathway interaction
- Best for visceral fat reduction in metabolically compromised populations; less pronounced subcutaneous fat loss than CJC + Ipa stack
- GHRP-2 / GHRP-6
- Non-selective ghrelin agonists; stimulate GH, cortisol, and prolactin
- ~30 min
- HSL activation via GH; significant appetite stimulation (ghrelin pathway)
- Elevates cortisol 20–40%; increases prolactin; strong hunger response limits fat loss efficacy
- Effective for muscle gain but poor for fat loss due to appetite and cortisol profile; replaced by Ipamorelin in modern protocols
- Semaglutide / Tirzepatide (GLP-1)
- GLP-1 receptor agonist; slows gastric emptying, reduces appetite centrally
- 5–7 days
- Caloric restriction via appetite suppression; no direct lipolytic signalling
- GI side effects (nausea, vomiting) in 30–45% during titration; no lean mass preservation
- Best for individuals with 25%+ body fat or metabolic dysfunction; works through caloric deficit, not substrate partitioning
- CJC-1295 with DAC
- GHRH analogue with Drug Affinity Complex; continuous GH elevation for 7–14 days
- 6–8 days
- Continuous GH elevation activates HSL but also induces insulin resistance over time
- Prolonged receptor occupancy desensitises pituitary; risk of acromegaly-like effects at high doses
- Useful for muscle gain; inferior to 'no DAC' version for fat loss due to insulin resistance induction
- The CJC-1295 no DAC & Ipamorelin stack occupies a unique position: it's the only combination that amplifies natural GH pulses (preserving pituitary sensitivity) without cortisol or appetite side effects (preserving metabolic context). AOD-9604 offers direct lipolysis without anabolic effects, making it complementary rather than competitive. Some research protocols stack AOD with CJC + Ipamorelin for additive fat oxidation. GLP-1 agonists like Tirzepatide work through entirely different mechanisms (appetite suppression and caloric deficit) and are best suited for obese populations; GH secretagogues work in already-lean individuals targeting single-digit body fat percentages.